Medline is converting hospital share into a public-company earnings problem. The Northfield manufacturer-distributor just posted another quarter of double-digit sales growth while cutting full-year adjusted earnings, the earnings before interest, taxes, depreciation and amortization after add-backs. That split is the entire post-listing debate. Prime Vendor wins, the multi-year contracts under which a health system buys most of its medical-surgical supplies from one partner, keep landing. The equity is no longer paying for an uninterrupted climb in cash profit. Investors are being asked to decide whether share gains bought with labor, quality spend, and price concessions still compound into a manufacturer-like franchise, or whether the listing simply revealed a high-volume distributor that cannot hold the private-market margin story.
Adjusted earnings of $1,060 million in the second quarter still rose, but the print includes a $243 million net tariff refund. Strip that refund and the quarter does not show operating leverage. Management raised organic sales guidance and lowered the adjusted-earnings range in the same breath. The Tracy, California warehouse fire and a quality build-out explain part of the cut. The rest is more structural: Supply Chain Solutions is growing faster than the higher-margin Medline Brand line, retail is soft inside Brand, and labor is being hired months before new contracts bill. That is share-taking economics, not a one-quarter accident.
Net sales reached $7,685 million. Reported net income fell by more than half after a $336 million fire charge booked before insurance recoveries. Cash generation stayed healthy in the first half, and net leverage is now inside the long-stated band below three times adjusted earnings. The stock last traded near $32, well below the December listing price and far under the post-listing peak. The question for the next several quarters is simple. Does Brand mix and cost absorption recover as the new accounts mature, or does the company keep buying volume that never returns the promised profit?